Safety, Tolerability and PK of PXL770 in Healthy Male Subjects
Status:
Completed
Trial end date:
2018-03-16
Target enrollment:
Participant gender:
Summary
PXL770 is a direct activator of 5' adenosine monophosphate-activated protein kinase (AMPK)
being developed by Poxel S.A. for the treatment of type 2 diabetes mellitus (T2DM). In Part A
of this study, we'll test the safety, tolerability and pharmacokinetics (PK) of repeated
doses. In Part B, we'll co-administer PXL770 and rosuvastatin (a HMG-CoA reductase inhibitor)
to assess any drug-drug interaction.